Navigation Links
Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
Date:9/10/2007

Managed Care Organizations Aggressively Control Access to Biologics,

According to a New Report from Decision Resources

WALTHAM, Mass., Sept. 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that specialists are turning to biologics earlier in the course of treatment for psoriasis and psoriatic arthritis. According to the new Physician & Payer Forum report entitled Psoriasis and Psoriatic Arthritis: The Expanding Biologics Landscape, surveyed dermatologists last year tried an average of 5.8 therapies for moderate psoriasis before turning to biologics. By mid-2008 they will try only 2.1 other therapies before turning to biologics. Likewise for axial psoriatic arthritis, rheumatologists tried an average of 4.1 other therapies prior to biologics last year; by mid-2008 they will only try 1.7 nonbiologics.

Specialists say the role of biologics will expand through mid-2008. Seventy-two percent of dermatologists and 90% of rheumatologists say they will write more scripts for biologics for psoriasis and psoriatic arthritis, respectively, through mid-2008. These specialists estimate that their use of biologics will increase by 9.9 percent in psoriasis and 11.9 percent in psoriatic arthritis.

In contrast to clinicians' increasingly aggressive use of biologics, the report also finds that managed care organizations (MCOs) are restricting access to biologics.

"By mid-2008, one half of surveyed MCOs' private plans will have step therapy protocols in place and 14 out of 20 surveyed MCOs will impose prior authorization for Enbrel, the leading biologic agent, for psoriasis therapy," said Joanna Kim, analyst at Decision Resources. "Physicians estimate that biologic therapy is currently delayed in 30-45% of their patients because of step therapy protocols imposed by MCOs. And overall, specialists perceive biologics to be less accessible for the treatment of psoriasis than psoriatic arthritis.

Psoriasis and Psoriatic Arthritis: The Expanding Biologics Landscape is based on a U.S. survey of 50 dermatologists, 51 rheumatologists and 20 managed care pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical and economic, factors in the management of psoriasis and Psoriatic arthritis with biologic therapies.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high-volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sonic closer to turning profit corner
2. Turning ads into sales: Context is king
3. Turning Around a Sick Company
4. GE Healthcare technology helping to detect Alzheimers earlier
5. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
6. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
7. Quintessence cancer treatment chosen for clinical studies
8. ZyStor to exhibit cell disorder treatments
9. Radiology advance points way to non-invasive brain-cancer treatment
10. Animal testing: Beyond the protests, instances of mistreatment are rare
11. TomoTherapy leads the industry in CT image-guided treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... Charlotte, N.C. (PRWEB) , ... October 09, 2017 , ... ... Purple announced Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and ... Dr. Stubbs was a member of the winning team for the 2015 Breakthrough Prize ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially ... cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture Network (HTVN) ... their fourth annual Conference where founders, investors, innovative practitioners and collaborators are invited ... competition showcasing early stage digital health and med tech companies. , This day-long ...
Breaking Biology Technology:
(Date:5/23/2017)... Italy , May 23, 2017  Hunova, the first robotic gym ... trunk, has been officially launched in Genoa, Italy . ... Europe and the USA . The technology ... on the market by the IIT spin-off Movendo Technology thanks to a ... the Multimedia News Release, please click: ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/18/2017)... -- Socionext Inc., a global expert in SoC-based imaging and computing solutions, ... which features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ... will be showcased during the upcoming Medtec Japan at Tokyo Big ... Las Vegas Convention Center April 24-27. ... Click here for an image of ...
Breaking Biology News(10 mins):